Researchers at Kazakh National Agrarian Research University engineered a monoclonal antibody administered intranasally that prevents pollen-induced hay fever and asthma symptoms in mice sensitized to mugwort pollen. Published in Frontiers in Immunology, this is the first demonstration of nasal antibody delivery targeting a pollen allergen, suggesting a needle-free precision therapy approach. The work offers a potential new treatment paradigm for aeroallergen-driven allergic rhinitis and asthma affecting millions.